According to an article posted on BioPharma-Reporter.com, a significant new study with canines successfully preserved the vision of dogs suffering with naturally occurring, late-stage retinitis pigmentosa. The article, “Animal study shows benefit from gene therapy in late-stage eye disease,” notes that until now, studies had shown promise of gene therapy but only if used in early stages of the disease.
This taxpayer-funded research, funded by the National Institutes of Health’s (NIH) National Eye Institute (NEI) showed improved retinal cells and prevented vision loss for two years in dogs. This is an important advancement as NEI scientists expect human trials to being in a few years. Retinitis pigmentosa is the most common inherited disease causing degeneration of the retina with approximately 1 in 4,000 peopled impacted by the mutation of the RPGR (retinitis pigmentosa GTPase regulator) gene.
To learn more about this discovery, please read the article by clicking here.